SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Roger Cranwill who wrote (1273)9/19/1997 11:33:00 AM
From: Roudy   of 1762
 
Good morning Roger, Thanks for the feedback. I have to agree about catching a tiger by the tail. Once we get full FDA approval, I think we will see more of the public spotlight. A new cancer treatment available on the market has to be news worthy. Science has been working for years to break the ice on a better way to beat cancer. And I think this is the beginning of many new therapies to come over the next decade. The next year with IDEC is going to be exciting with Rituxan making sales and IDEC's pipeline of other therapies making further development. Don
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News